title: Checkpoint inhibitors: outstanding efficacy but at what cost?
authors.affiliation: Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Jean A
authors.initials: JA
authors.lastname: Klastersky
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors / Q000378:metabolism; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors / Q000378:metabolism; D000071877:Checkpoint Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D064447:Checkpoint Kinase 2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D060908:CTLA-4 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D047428:Protein Kinase Inhibitors; D064447:Checkpoint Kinase 2; D000071877:Checkpoint Kinase 1